Skip to content

One challenge which has emerged with the introduction of CAB for PrEP is the risk of Integrase Strand Transfer Inhibitor (INSTI) resistance amongst people who acquire HIV while taking CAB as prescribed. To address emerging evidence around testing algorithms and INSTI resistance in CAB users, AVAC and WHO convened a think tank with program implementers, testing experts, mathematical modelers, policy makers, donors, and civil society.

Featured Resources